Deep Brain Stimulation for Arm Tremor: A Randomized Trial Comparing Two Targets.

"Potential Conflicts of Interest Medtronic® and Boston Scientific® are both manufacturers of the DBS devices that have been used in this study. NK reports travel support from Medtronic to participate in a DBS course arranged by them. AEK reports travel support from Boston Scientific to attend a scientific meeting about DBS arranged by them. MMR reports consulting fees and honoraria for lectures from Boston Scientific and Medtronic, and from Boston Scientific also grants, board participation, and travel support for attending meetings, not directly related to the submitted work. JV reports grants and personal fees from Boston Scientific, grants and personal fees from Medtronic, and personal fees from Abbott St. Jude and Newronika (both manufacturers of DBS devices), not directly related to the submitted work. ED reports honoraria for lectures from AbbVie, Lobsor and Nordic Infucare (all manufacturers of dopaminergic medication pumps). IMS reports honoraria for lectures at scientific meetings and courses about DBS from Boston Scientific, arranged by them. None of the activities mentioned above were directly related to the submitted work. JR and AHP report no conflicts of interest."

"We are very grateful for the grant from the South‐Eastern Regional Health Authorities awarded to Inger Marie Skogseid. She was also supported by private donations (from two patients outside the study) to the Department of Neurology, Research section. Editorial assistance was provided by a native English speaker (Deborah Nock, Medical WriteAway, Norwich, UK)."

"Study participants were recruited consecutively from patients with severe tremor evaluated and accepted for DBS treatment at our center. Eligible patients were males and females, aged 18 to 80 years, with chronic action UL tremor interfering with work performance and/or activities of daily living, and insufficient relief from adequate trials of recommended medications. Prior diagnostic work‐up included brain MRI in all, DATscan in patients with rest tremor, and blood and urine tests to exclude medically‐treatable disorders. Eligible tremor disorders were ET/ET plus, PD, dystonic tremor, and cerebellar tremor (idiopathic or secondary to MS or spino‐cerebellar ataxia). Exclusion criteria included the usual contraindications to DBS surgery, and comorbidities which would make evaluation of the beneficial and adverse stimulation effects challenging (eg, severe peripheral neuropathy, chronic pain syndrome with opioid use). Written informed consent was obtained from each patient before enrolment. The study was performed according to the Helsinki declaration. Trial registration: ClinicalTrials.gov (NCT03156517)."